3/27
04:50 pm
mack
Merrimack Receives $225 Million Milestone Payment from Ipsen [Yahoo! Finance]
Low
Report
Merrimack Receives $225 Million Milestone Payment from Ipsen [Yahoo! Finance]
3/27
04:30 pm
mack
Merrimack Receives $225 Million Milestone Payment from Ipsen
Low
Report
Merrimack Receives $225 Million Milestone Payment from Ipsen
3/7
04:30 pm
mack
Merrimack Reports Full Year 2023 Financial Results
Low
Report
Merrimack Reports Full Year 2023 Financial Results
3/4
07:17 am
mack
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company [Yahoo! Finance]
Low
Report
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company [Yahoo! Finance]
2/13
04:51 pm
mack
Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA Approval [MarketWatch]
Low
Report
Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA Approval [MarketWatch]
2/13
04:26 pm
mack
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) [Yahoo!
Low
Report
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) [Yahoo!
2/13
04:18 pm
mack
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Medium
Report
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
1/31
01:08 am
mack
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.